These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 29600973

  • 1. Signatures of anti-Thomsen - Friedenreich antigen antibody diversity in colon cancer patients.
    Kurtenkov O, Bubina M, Klaamas K.
    Exp Oncol; 2018 Mar; 40(1):48-58. PubMed ID: 29600973
    [Abstract] [Full Text] [Related]

  • 2. Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.
    Kodar K, Izotova J, Klaamas K, Sergeyev B, Järvekülg L, Kurtenkov O.
    World J Gastroenterol; 2013 Jun 21; 19(23):3573-82. PubMed ID: 23801858
    [Abstract] [Full Text] [Related]

  • 3. The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
    Kurtenkov O, Innos K, Sergejev B, Klaamas K.
    Biomed Res Int; 2018 Jun 21; 2018():9579828. PubMed ID: 30105268
    [Abstract] [Full Text] [Related]

  • 4. Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.
    Kurtenkov O, Klaamas K.
    Dis Markers; 2015 Jun 21; 2015():761908. PubMed ID: 26663951
    [Abstract] [Full Text] [Related]

  • 5. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
    Kurtenkov O, Izotova J, Klaamas K, Sergeyev B.
    Biomed Res Int; 2014 Jun 21; 2014():830847. PubMed ID: 25276822
    [Abstract] [Full Text] [Related]

  • 6. Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.
    Kurtenkov O, Klaamas K.
    Biomed Res Int; 2017 Jun 21; 2017():6097647. PubMed ID: 28316982
    [Abstract] [Full Text] [Related]

  • 7. The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients.
    Kodar K, Kurtenkov O, Klaamas K.
    Immunol Invest; 2009 Jun 21; 38(8):704-17. PubMed ID: 19860583
    [Abstract] [Full Text] [Related]

  • 8. Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients.
    Smorodin EP, Kurtenkov OA, Sergeyev BL, Kodar KE, Chuzmarov VI, Afanasyev VP.
    World J Gastroenterol; 2008 Jul 21; 14(27):4352-8. PubMed ID: 18666325
    [Abstract] [Full Text] [Related]

  • 9. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
    MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T.
    J Immunother (1991); 1992 May 21; 11(4):292-305. PubMed ID: 1599915
    [Abstract] [Full Text] [Related]

  • 10. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
    Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V.
    Acta Oncol; 2007 May 21; 46(3):316-23. PubMed ID: 17450466
    [Abstract] [Full Text] [Related]

  • 11. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.
    Cancer Immunol Immunother; 2005 Jul 21; 54(7):694-702. PubMed ID: 15726361
    [Abstract] [Full Text] [Related]

  • 12. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin.
    Campbell BJ, Finnie IA, Hounsell EF, Rhodes JM.
    J Clin Invest; 1995 Feb 21; 95(2):571-6. PubMed ID: 7860740
    [Abstract] [Full Text] [Related]

  • 13. The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.
    Smorodin E, Sergeyev B, Klaamas K, Chuzmarov V, Kurtenkov O.
    Int J Med Sci; 2013 Feb 21; 10(12):1674-82. PubMed ID: 24151439
    [Abstract] [Full Text] [Related]

  • 14. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.
    Kurtenkov O, Klaamas K, Rittenhouse-Olson K, Vahter L, Sergejev B, Miljukhina L, Shljapnikova L.
    Exp Oncol; 2005 Jun 21; 27(2):136-40. PubMed ID: 15995632
    [Abstract] [Full Text] [Related]

  • 15. Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.
    Kurtenkov O.
    Biomed Res Int; 2020 Jun 21; 2020():9747040. PubMed ID: 32280709
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cluster binding studies with two anti-Thomsen-Friedenreich (anti-core-1, CD176, TF) antibodies: Evidence for a multiple TF epitope.
    Flechner A, Butschak G, Löffler A, Rühmann J, Nishimura SI, Dölling R, Purfürst B, Goletz S, Danielczyk A, Karsten U.
    Int Immunopharmacol; 2019 Jul 21; 72():186-194. PubMed ID: 30999209
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.